Company Description
Tempus AI, Inc. operates as a healthcare technology company.
It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies.
In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data.
The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology, as well as strategic collaboration with Personalis, Inc. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023.
Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 14, 2024 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 2,400 |
| CEO | Eric Lefkofsky |
Contact Details
Address: 600 West Chicago Avenue, Suite 510 Chicago, Illinois 60654 United States | |
| Phone | 800 976 5448 |
| Website | tempus.com |
Stock Details
| Ticker Symbol | TEM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $37.00 |
| CIK Code | 0001717115 |
| CUSIP Number | 71535D106 |
| ISIN Number | US88023B1035 |
| Employer ID | 47-4903308 |
| SIC Code | 7370 |
Key Executives
| Name | Position |
|---|---|
| Eric P. Lefkofsky J.D. | Co-Founder, Chief Executive Officer, President and Chairman |
| Ryan Fukushima | Chief Operating Officer |
| Andrew Polovin | Executive Vice President, General Counsel and Secretary |
| James Rogers | Chief Financial Officer |
| Ryan M. Bartolucci CPA | Chief Accounting Officer |
| Shane Colley | Chief Technology Officer |
| Dr. Kate A. Sasser Ph.D. | Chief Scientific Officer |
| Erik Phelps | Executive Vice President, Assistant Secretary and Chief Administrative and Legal Officer |
| Elizabeth Krutoholow | Vice President of Investor Relations and Competitive Intelligence |
| Patty Spiller | Chief Marketing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2025 | PRE 14C | Filing |
| Aug 8, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 8, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 8, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Aug 8, 2025 | 10-Q | Quarterly Report |
| Aug 8, 2025 | 8-K | Current Report |
| Aug 1, 2025 | 144 | Filing |
| Jul 28, 2025 | 144 | Filing |
| Jul 7, 2025 | 144 | Filing |
| Jul 3, 2025 | 8-K | Current Report |